Monday, February 20, 2023 4:28:29 PM
FFS, you say and earlier state "1- JPMorgan is made aware of Sarissa’s intentions and ignites a short squeeze with an AMRN upgrade"
Sounds like you mistakenly think the upgrade was by JPM when it was in fact by Jefferies.
https://www.benzinga.com/news/23/01/30307116/jefferies-upgrades-amarin-corp-to-buy-raises-price-target-to-3
https://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Amarin+Corporation+%28AMRN%29+to+Buy/21042047.html
https://www.marketscreener.com/quote/stock/AMARIN-CORPORATION-PLC-1658813/news-broker-research/
JPM on market screener shows 05/06/2022 "JPMorgan Downgrades Amarin to Underweight From Neutral" and JP Morgan analyst Wolle's last analyst action appears to be a SELL recommendation initiated on Jul 31, 2022 (no price target). ... which I earlier commented was odd as they are serving as Amarin's financial advisor. [Post #399096]
dogn
JPM initiated the squeeze,
Sounds like you mistakenly think the upgrade was by JPM when it was in fact by Jefferies.
https://www.benzinga.com/news/23/01/30307116/jefferies-upgrades-amarin-corp-to-buy-raises-price-target-to-3
https://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Amarin+Corporation+%28AMRN%29+to+Buy/21042047.html
https://www.marketscreener.com/quote/stock/AMARIN-CORPORATION-PLC-1658813/news-broker-research/
JPM on market screener shows 05/06/2022 "JPMorgan Downgrades Amarin to Underweight From Neutral" and JP Morgan analyst Wolle's last analyst action appears to be a SELL recommendation initiated on Jul 31, 2022 (no price target). ... which I earlier commented was odd as they are serving as Amarin's financial advisor. [Post #399096]
dogn
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
